Published in Infect Immun on January 01, 2002
Killed but metabolically active Leishmania infantum as a novel whole-cell vaccine for visceral leishmaniasis. Clin Vaccine Immunol (2012) 1.49
The RNA-binding protein TbDRBD3 regulates the stability of a specific subset of mRNAs in trypanosomes. Nucleic Acids Res (2008) 1.32
Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis. Infect Immun (2005) 1.11
Development of Vaccines against Visceral Leishmaniasis. J Trop Med (2011) 1.03
Characterization of a Leishmania stage-specific mitochondrial membrane protein that enhances the activity of cytochrome c oxidase and its role in virulence. Mol Microbiol (2010) 0.96
Live attenuated Leishmania donovani p27 gene knockout parasites are nonpathogenic and elicit long-term protective immunity in BALB/c mice. J Immunol (2013) 0.92
Recombinant Leishmania major secreting biologically active granulocyte-macrophage colony-stimulating factor survives poorly in macrophages in vitro and delays disease development in mice. Infect Immun (2003) 0.92
Adjuvants for Leishmania vaccines: from models to clinical application. Front Immunol (2012) 0.92
Leishmania infantum HSP70-II null mutant as candidate vaccine against leishmaniasis: a preliminary evaluation. Parasit Vectors (2011) 0.91
Immunity to visceral leishmaniasis using genetically defined live-attenuated parasites. J Trop Med (2011) 0.91
Photodynamic vaccination of hamsters with inducible suicidal mutants of Leishmania amazonensis elicits immunity against visceral leishmaniasis. Eur J Immunol (2009) 0.90
Vaccine Development Against Leishmania donovani. Front Immunol (2012) 0.90
Development of novel prime-boost strategies based on a tri-gene fusion recombinant L. tarentolae vaccine against experimental murine visceral leishmaniasis. PLoS Negl Trop Dis (2013) 0.89
Genetically modified organisms and visceral leishmaniasis. Front Immunol (2014) 0.88
Transgenic Leishmania and the immune response to infection. Parasite Immunol (2008) 0.88
Visceral Leishmaniasis: Advancements in Vaccine Development via Classical and Molecular Approaches. Front Immunol (2014) 0.85
Biomarkers of safety and immune protection for genetically modified live attenuated leishmania vaccines against visceral leishmaniasis - discovery and implications. Front Immunol (2014) 0.82
Live vaccination tactics: possible approaches for controlling visceral leishmaniasis. Front Immunol (2014) 0.81
Knockout of the dhfr-ts gene in Trypanosoma cruzi generates attenuated parasites able to confer protection against a virulent challenge. PLoS Negl Trop Dis (2011) 0.80
Intradermal Immunization of Leishmania donovani Centrin Knock-Out Parasites in Combination with Salivary Protein LJM19 from Sand Fly Vector Induces a Durable Protective Immune Response in Hamsters. PLoS Negl Trop Dis (2016) 0.78
Genetically Engineered Ascorbic acid-deficient Live Mutants of Leishmania donovani induce long lasting Protective Immunity against Visceral Leishmaniasis. Sci Rep (2015) 0.77
Episomally driven antisense mRNA abrogates the hyperinducible expression and function of a unique cell surface class I nuclease in the primitive trypanosomatid parasite, Crithidia luciliae. J Mol Biol (2007) 0.77
UDP-Gal: N-acetylglucosamine beta 1-4 galactosyltransferase expressing live attenuated parasites as vaccine for visceral leishmaniasis. Glycoconj J (2008) 0.76
Cultivation and in vitro cloning or procyclic culture forms of Trypanosoma brucei in a semi-defined medium. Short communication. Acta Trop (1979) 8.43
Leishmaniasis. Lancet (1999) 7.20
Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis (1997) 4.23
Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis (2000) 3.72
Metabolism and functions of trypanothione in the Kinetoplastida. Annu Rev Microbiol (1992) 3.57
The role of nitric oxide in innate immunity. Immunol Rev (2000) 2.78
Leishmaniasis: current status of vaccine development. Clin Microbiol Rev (2001) 2.62
Loss of virulence in Leishmania donovani deficient in an amastigote-specific protein, A2. Proc Natl Acad Sci U S A (1997) 2.53
Episomal and stable expression of the luciferase reporter gene for quantifying Leishmania spp. infections in macrophages and in animal models. Mol Biochem Parasitol (2000) 2.10
Development of a safe live Leishmania vaccine line by gene replacement. Proc Natl Acad Sci U S A (1995) 1.99
Immunologic markers of clinical evolution in children recently infected with Leishmania donovani chagasi. J Infect Dis (1992) 1.90
Dendritic cells, but not macrophages, produce IL-12 immediately following Leishmania donovani infection. Eur J Immunol (1998) 1.89
Plasticity in chromosome number and testing of essential genes in Leishmania by targeting. Proc Natl Acad Sci U S A (1993) 1.88
Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan. Lancet (2000) 1.86
A novel antifolate resistance gene on the amplified H circle of Leishmania. EMBO J (1992) 1.82
Regulation of differentiation to the infective stage of the protozoan parasite Leishmania major by tetrahydrobiopterin. Science (2001) 1.77
Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis. J Immunol (2000) 1.72
Experimental visceral leishmaniasis: role of endogenous IFN-gamma in host defense and tissue granulomatous response. J Immunol (1989) 1.70
Leishmania mexicana cysteine proteinase-deficient mutants have attenuated virulence for mice and potentiate a Th1 response. J Immunol (1998) 1.59
Disruption of the trypanothione reductase gene of Leishmania decreases its ability to survive oxidative stress in macrophages. EMBO J (1997) 1.58
Splenic cytokine responses in Indian kala-azar before and after treatment. J Infect Dis (1998) 1.49
DNA transformation of Leishmania infantum axenic amastigotes and their use in drug screening. Antimicrob Agents Chemother (2001) 1.39
The growth and nutrition of Crithidia fasciculata. J Gen Microbiol (1958) 1.32
Autonomous replication of bacterial DNA plasmid oligomers in Leishmania. Mol Biochem Parasitol (1994) 1.28
New approaches to Leishmania chemotherapy: pteridine reductase 1 (PTR1) as a target and modulator of antifolate sensitivity. Parasitology (1997) 1.24
Leishmania major Hsp100 is required chiefly in the mammalian stage of the parasite. Mol Cell Biol (1997) 1.16
Selection against the dihydrofolate reductase-thymidylate synthase (DHFR-TS) locus as a probe of genetic alterations in Leishmania major. Mol Cell Biol (1996) 1.08
The capacity to produce IFN-gamma rather than the presence of interleukin-4 determines the resistance and the degree of susceptibility to Leishmania donovani infection in mice. J Interferon Cytokine Res (2000) 1.08
Cytokine-producing T cell subsets in human leishmaniasis. Arch Immunol Ther Exp (Warsz) (2000) 1.00
Leishmania-specific T cells expressing interferon-gamma (IFN-gamma) and IL-10 upon activation are expanded in individuals cured of visceral leishmaniasis. Clin Exp Immunol (1999) 1.00
Gene disruptions indicate an essential function for the LmmCRK1 cdc2-related kinase of Leishmania mexicana. Mol Microbiol (1996) 0.97
Subunit vaccination of mice against new world cutaneous leishmaniasis: comparison of three proteins expressed in amastigotes and six adjuvants. Infect Immun (2000) 0.94
Pteridine requirement of the hemoflagellate Leishmania tarentolae. J Protozool (1969) 0.94
Protection against Leishmania major challenge infection in mice vaccinated with live recombinant parasites expressing a cytotoxic gene. J Infect Dis (1998) 0.93
An amplified DNA element in Leishmania encodes potential integral membrane and nucleotide-binding proteins. Mol Biochem Parasitol (1994) 0.89
LD1 amplifications in Leishmania. Parasitol Today (1997) 0.87
Immunization with recombinant LD1 antigens protects against experimental leishmaniasis. Vaccine (2000) 0.84
The Leishmania donovani LD1 locus gene ORFG encodes a biopterin transporter (BT1). Mol Biochem Parasitol (1999) 0.83
Adaptation of Leishmania cells to in vitro culture results in a more efficient reduction and transport of biopterin. Exp Parasitol (2001) 0.83
The Leishmania infantum acidic ribosomal protein LiP2a induces a prominent humoral response in vivo and stimulates cell proliferation in vitro and interferon-gamma (IFN-gamma) production by murine splenocytes. Clin Exp Immunol (2000) 0.80
Antifolate resistance mechanisms from bacteria to cancer cells with emphasis on parasites. Adv Exp Med Biol (1998) 0.77
Importance of lymphokines in the control of multiplication and dispersion of Leishmania donovani within liver macrophages of resistant and susceptible mice. J Parasitol (1989) 0.77
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med (2009) 14.13
Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med (2010) 5.48
Malaria hemozoin is immunologically inert but radically enhances innate responses by presenting malaria DNA to Toll-like receptor 9. Proc Natl Acad Sci U S A (2007) 3.41
Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int (2008) 3.34
Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol (2008) 2.72
Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol (2007) 2.62
Unresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites. PLoS Med (2006) 2.60
Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. Am J Kidney Dis (2008) 2.31
A comparison of prediction equations for estimating glomerular filtration rate in adults without kidney disease. J Am Soc Nephrol (2003) 2.23
Malarial hemozoin activates the NLRP3 inflammasome through Lyn and Syk kinases. PLoS Pathog (2009) 2.07
Leishmania repression of host translation through mTOR cleavage is required for parasite survival and infection. Cell Host Microbe (2011) 2.01
Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation (2011) 1.87
Drug uptake and modulation of drug resistance in Leishmania by an aquaglyceroporin. J Biol Chem (2004) 1.79
Hypertension in the developing world: challenges and opportunities. Am J Kidney Dis (2009) 1.79
Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from Leishmania involved in drug resistance. J Biol Chem (2003) 1.76
Kidney pathological changes in metabolic syndrome: a cross-sectional study. Am J Kidney Dis (2009) 1.74
A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment. Kidney Int (2009) 1.72
Pure red cell aplasia due to follow-on epoetin. Kidney Int (2008) 1.69
Fournier gangrene: role of imaging. Radiographics (2008) 1.68
Anemia management and association of race with mortality and hospitalization in a large not-for-profit dialysis organization. Am J Kidney Dis (2009) 1.66
Prefractionation by digitonin extraction increases representation of the cytosolic and intracellular proteome of Leishmania infantum. J Proteome Res (2006) 1.65
Resistance to antimony and treatment failure in human Leishmania (Viannia) infection. J Infect Dis (2006) 1.62
Leishmania major LmACR2 is a pentavalent antimony reductase that confers sensitivity to the drug pentostam. J Biol Chem (2004) 1.60
Use of tuf sequences for genus-specific PCR detection and phylogenetic analysis of 28 streptococcal species. J Clin Microbiol (2004) 1.51
A common mechanism of stage-regulated gene expression in Leishmania mediated by a conserved 3'-untranslated region element. J Biol Chem (2002) 1.48
Genome-wide gene expression profiling analysis of Leishmania major and Leishmania infantum developmental stages reveals substantial differences between the two species. BMC Genomics (2008) 1.47
Hemozoin-inducible proinflammatory events in vivo: potential role in malaria infection. J Immunol (2004) 1.46
Alcohol and sexual risk behavior among migrant female sex workers and male workers in districts with high in-migration from four high HIV prevalence states in India. AIDS Behav (2010) 1.43
Ferric gluconate treatment provides cost savings in patients with high ferritin and low transferrin saturation. Kidney Int (2008) 1.43
Acute coronary syndrome in ESRD patients. Kidney Int (2008) 1.43
Leishmania-induced cellular recruitment during the early inflammatory response: modulation of proinflammatory mediators. J Infect Dis (2002) 1.42
The SHP-1 protein tyrosine phosphatase negatively modulates glucose homeostasis. Nat Med (2006) 1.42
Biochemical characterization of Leishmania major aquaglyceroporin LmAQP1: possible role in volume regulation and osmotaxis. Mol Microbiol (2007) 1.39
Role of ABC transporter MRPA, gamma-glutamylcysteine synthetase and ornithine decarboxylase in natural antimony-resistant isolates of Leishmania donovani. J Antimicrob Chemother (2007) 1.38
Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm. Am J Kidney Dis (2012) 1.38
Modulation of gene expression in drug resistant Leishmania is associated with gene amplification, gene deletion and chromosome aneuploidy. Genome Biol (2008) 1.38
Genome sequencing of linezolid-resistant Streptococcus pneumoniae mutants reveals novel mechanisms of resistance. Genome Res (2009) 1.37
Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route. Infect Immun (2007) 1.37
Hemozoin induces macrophage chemokine expression through oxidative stress-dependent and -independent mechanisms. J Immunol (2005) 1.36
A proteomics screen implicates HSP83 and a small kinetoplastid calpain-related protein in drug resistance in Leishmania donovani clinical field isolates by modulating drug-induced programmed cell death. Mol Cell Proteomics (2006) 1.36
Modulation in aquaglyceroporin AQP1 gene transcript levels in drug-resistant Leishmania. Mol Microbiol (2005) 1.35
Association of anemia and erythropoiesis stimulating agents with inflammatory biomarkers in chronic kidney disease. Kidney Int (2008) 1.34
Frequency of and risk factors for poor cognitive performance in hemodialysis patients. Neurology (2013) 1.34
Prevalence and risk factors of chronic kidney disease in the Thai adult population: Thai SEEK study. Nephrol Dial Transplant (2009) 1.33
Leishmania GP63 alters host signaling through cleavage-activated protein tyrosine phosphatases. Sci Signal (2009) 1.32
Characterization and developmental gene regulation of a large gene family encoding amastin surface proteins in Leishmania spp. Mol Biochem Parasitol (2005) 1.30
Antimony uptake systems in the protozoan parasite Leishmania and accumulation differences in antimony-resistant parasites. Antimicrob Agents Chemother (2003) 1.29
Role of host protein tyrosine phosphatase SHP-1 in Leishmania donovani-induced inhibition of nitric oxide production. Infect Immun (2006) 1.29
Hemozoin increases IFN-gamma-inducible macrophage nitric oxide generation through extracellular signal-regulated kinase- and NF-kappa B-dependent pathways. J Immunol (2003) 1.29
Whole-genome comparative RNA expression profiling of axenic and intracellular amastigote forms of Leishmania infantum. Mol Biochem Parasitol (2009) 1.28
Thiol-induced reduction of antimony(V) into antimony(III): a comparative study with trypanothione, cysteinyl-glycine, cysteine and glutathione. Biometals (2003) 1.27
Gene expression modulation is associated with gene amplification, supernumerary chromosomes and chromosome loss in antimony-resistant Leishmania infantum. Nucleic Acids Res (2009) 1.27
Disclosure of the HIV infection status in children. Indian J Pediatr (2009) 1.27
Inflammation-driven reprogramming of CD4+ Foxp3+ regulatory T cells into pathogenic Th1/Th17 T effectors is abrogated by mTOR inhibition in vivo. PLoS One (2012) 1.26
Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J (2005) 1.25
Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum. Clin Infect Dis (2009) 1.25
A combined proteomic and transcriptomic approach to the study of stage differentiation in Leishmania infantum. Proteomics (2006) 1.24
Role of the ABC transporter MRPA (PGPA) in antimony resistance in Leishmania infantum axenic and intracellular amastigotes. Antimicrob Agents Chemother (2005) 1.24
Genome sequencing of the lizard parasite Leishmania tarentolae reveals loss of genes associated to the intracellular stage of human pathogenic species. Nucleic Acids Res (2011) 1.23
The Leishmania surface protease GP63 cleaves multiple intracellular proteins and actively participates in p38 mitogen-activated protein kinase inactivation. J Biol Chem (2008) 1.22
Host-pathogen interactions of Actinobacillus pleuropneumoniae with porcine lung and tracheal epithelial cells. Infect Immun (2009) 1.22
Encapsulated Streptococcus suis inhibits activation of signaling pathways involved in phagocytosis. Infect Immun (2004) 1.20
Aerosol chemistry over a high altitude station at northeastern Himalayas, India. PLoS One (2010) 1.19
Signalling events involved in interferon-gamma-inducible macrophage nitric oxide generation. Immunology (2003) 1.19
Epstein-Barr virus induces MCP-1 secretion by human monocytes via TLR2. J Virol (2007) 1.17
Does TREAT give the boot to ESAs in the treatment of CKD anemia? J Am Soc Nephrol (2009) 1.17
Modulation of gene expression in Leishmania drug resistant mutants as determined by targeted DNA microarrays. Nucleic Acids Res (2003) 1.16
Inherited human OX40 deficiency underlying classic Kaposi sarcoma of childhood. J Exp Med (2013) 1.14
Host cell signalling and leishmania mechanisms of evasion. J Trop Med (2011) 1.13
Genome annotation and intraviral interactome for the Streptococcus pneumoniae virulent phage Dp-1. J Bacteriol (2010) 1.12
Leishmania-induced inactivation of the macrophage transcription factor AP-1 is mediated by the parasite metalloprotease GP63. PLoS Pathog (2010) 1.12
Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis. Infect Immun (2005) 1.11
A novel form of NF-kappaB is induced by Leishmania infection: involvement in macrophage gene expression. Eur J Immunol (2008) 1.11
Formation of linear inverted repeat amplicons following targeting of an essential gene in Leishmania. Nucleic Acids Res (2005) 1.11
Leishmania-induced IRAK-1 inactivation is mediated by SHP-1 interacting with an evolutionarily conserved KTIM motif. PLoS Negl Trop Dis (2008) 1.10
Synthetic Plasmodium-like hemozoin activates the immune response: a morphology - function study. PLoS One (2009) 1.10
Con: Randomized controlled trials (RCT) have failed in the study of dialysis methods. Nephrol Dial Transplant (2013) 1.09
Modulation of Leishmania ABC protein gene expression through life stages and among drug-resistant parasites. Eukaryot Cell (2006) 1.09
Innate inflammatory response to the malarial pigment hemozoin. Microbes Infect (2010) 1.07
Proinflammatory cytokine and chemokine modulation by Streptococcus suis in a whole-blood culture system. FEMS Immunol Med Microbiol (2006) 1.07
Pterin transport and metabolism in Leishmania and related trypanosomatid parasites. Int J Parasitol (2002) 1.07
Multiple mutations in heterogeneous miltefosine-resistant Leishmania major population as determined by whole genome sequencing. PLoS Negl Trop Dis (2012) 1.06
Microfluidic device for rapid (<15 min) automated microarray hybridization. Clin Chem (2005) 1.06
Whole genome analysis of linezolid resistance in Streptococcus pneumoniae reveals resistance and compensatory mutations. BMC Genomics (2011) 1.06
Promastigote to amastigote differentiation of Leishmania is markedly delayed in the absence of PERK eIF2alpha kinase-dependent eIF2alpha phosphorylation. Cell Microbiol (2011) 1.06
Polymer thin films embedded with metal nanoparticles for electrochemical biosensors applications. Biosens Bioelectron (2012) 1.06
Myeloid-related proteins rapidly modulate macrophage nitric oxide production during innate immune response. J Immunol (2008) 1.05
Comparison of the effects of Leishmania major or Leishmania donovani infection on macrophage gene expression. Infect Immun (2007) 1.04
The role of reduced pterins in resistance to reactive oxygen and nitrogen intermediates in the protozoan parasite Leishmania. Free Radic Biol Med (2008) 1.04
Intracellular survival of Leishmania species that cause visceral leishmaniasis is significantly reduced by HIV-1 protease inhibitors. J Infect Dis (2008) 1.03
Proteasome-mediated degradation of STAT1alpha following infection of macrophages with Leishmania donovani. J Biol Chem (2005) 1.02